Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pregabalin, quantity: 225 mg - capsule, hard - excipient ingredients: maize starch; lactose monohydrate; sodium lauryl sulfate; gelatin; iron oxide red; purified water; purified talc; titanium dioxide - pregabalin-drla (pregabalin) is indicated for the treatment of neuropathic pain in adults.,pregabalin-drla (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; titanium dioxide; indigo carmine; purified water; sorbitan monolaurate; erythrosine; gelatin; iron oxide black; sodium lauryl sulfate; propylene glycol; brilliant blue fcf; butan-1-ol; quinoline yellow; allura red ac; sd alcohol 45; sd alcohol 3-a - treatment of hypertension. data are currently not available to support the use of tryzan caps in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 5 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; propylene glycol; brilliant blue fcf; indigo carmine; butan-1-ol; quinoline yellow; allura red ac; iron oxide black; sd alcohol 45; sd alcohol 3-a; titanium dioxide; purified water; sorbitan monolaurate; erythrosine; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of tryzan caps in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 2.5 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; propylene glycol; brilliant blue fcf; indigo carmine; butan-1-ol; quinoline yellow; allura red ac; iron oxide black; sd alcohol 45; sd alcohol 3-a; titanium dioxide; purified water; iron oxide yellow; sorbitan monolaurate; erythrosine; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of tryzan caps in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 1.25 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; titanium dioxide; purified water; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate; propylene glycol; brilliant blue fcf; indigo carmine; butan-1-ol; quinoline yellow; allura red ac; iron oxide black; sd alcohol 45; sd alcohol 3-a - treatment of hypertension. data are currently not available to support the use of tryzan caps in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease

Israel - English - Ministry of Health

rafa laboratories ltd - budesonide - capsules - budesonide 3 mg - budesonide - acute mild to moderate crohn’s disease with involvement of the ileum (twisted intestine) and/or ascending colon (part of large bowel). collagenous colitis.autoimmune hepatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

melrose laboratories pty ltd - glucosamine hydrochloride, quantity: 750 mg - capsule, hard - excipient ingredients: magnesium stearate; silicon dioxide; ascorbic acid; calcium hydrogen phosphate dihydrate; hypromellose; disodium edetate; potable water; potassium acetate; gellan gum - decrease/reduce/relieve mild joint aches and pains ; decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis ; helps maintain/supports healthy joint cartilage growth/development/production ; maintain/support joint health ; decrease/reduce/relieve mild joint inflammation/swelling

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - choline fenofibrate 178.8mg eqv fenofibric acid - capsule, delayed release pellets - 135mg - choline fenofibrate 178.8mg eqv fenofibric acid 135mg

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - choline fenofibrate 59.6mg eqv fenofibric acid - capsule, delayed release pellets - 45mg - choline fenofibrate 59.6mg eqv fenofibric acid 45mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - celecoxib, quantity: 200 mg - capsule, hard - excipient ingredients: carrageenan; titanium dioxide; sodium lauryl sulfate; gelatin; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; iron oxide red; microcrystalline cellulose; iron oxide yellow; purified talc - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.